Metraipolis › archive › dc_d40329aec796

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial — Europe PMC PMID:42610717

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42610717
DOI
10.1093/rheumatology/keag420
License (as archived)
solo-consultazione
Archived
2026-10-16T07:42:03.740Z
SHA-256 of the archived text
2a274d8fa3801806720188ba0c8e45bf8e955a73c7f8284e28f12473a7ca0d29
Stable URL of this page
https://metraipolis.com/documento/dc_d40329aec796

How to cite

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial — Europe PMC PMID:42610717 — Europe PMC (en), https://europepmc.org/article/MED/42610717 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d40329aec796 (Metraipolis archive dc_d40329aec796, sha256 2a274d8fa3801806720188ba0c8e45bf8e955a73c7f8284e28f12473a7ca0d29)
BibTeX
@misc{dcd40329aec796,
  title = {Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial — Europe PMC PMID:42610717},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42610717},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d40329aec796; sha256 2a274d8fa3801806720188ba0c8e45bf8e955a73c7f8284e28f12473a7ca0d29},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42610717. Agents can read the archived copy with the MCP tool read_document.